- In November 2024, Johnson & Johnson announced that 43 presentations highlighting the company’s rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 Annual Meeting. The presentations will include three oral sessions and a plenary session, showcasing new data on the investigational drug nipocalimab for Sjögren's disease (SjD) and the latest research on the effects of TREMFYA® in psoriatic arthritis (PsA)
- In September 2024, UCB announced that U.S. FDA has approved BIMZELX for the treatment of adults with active psoriatic arthritis (PsA), adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondylitis. These newly approved indications follow the first U.S. approval for BIMZELX in October 2023 for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
- In June 2024, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara (sarilumab) for the treatment of patients weighing 63 kg or more with active polyarticular juvenile idiopathic arthritis (pJIA). This form of arthritis, which affects multiple joints simultaneously, can be particularly painful for children due to the chronic inflammation impacting several joints
- In October 2023, Novartis announced that the U.S. Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). Cosentyx is the first and only treatment available in an IV formulation that specifically targets and blocks interleukin-17A (IL-17A), and is also the only non-TNF-alpha IV treatment option approved for all of these indications
- In January 2023, Gilead Sciences, Inc. and EVOQ Therapeutics, Inc. (EVOQ) announced a collaboration and licensing agreement aimed at advancing EVOQ’s proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus. EVOQ’s NanoDisc technology is designed to facilitate the lymph-targeted delivery of disease-specific antigens, holding the potential to transform the treatment approach for autoimmune diseases
